Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

326
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
326
Bioavailability: Overview01:17

Bioavailability: Overview

396
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
396
Bioavailability: Overview01:13

Bioavailability: Overview

4.3K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.3K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

199
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
199
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

901
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
901
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

968
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
968

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spread of extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) in the community living spaces of patients identified as ESBL-E carriers: impact of the housing density in an African context.

Tropical medicine and health·2026
Same author

The orphan receptor GPR84 drives inflammation in Buruli ulcer development.

Science translational medicine·2026
Same author

Plasma and Brain Metabolomics Uncover Modulation of Bile Acid and Pentose Phosphate Pathways by <i>Melissa officinalis</i> in Obese Rat Model.

International journal of molecular sciences·2026
Same author

Lactuchelins represent lipopeptide siderophores produced by Pseudomonas lactucae that inhibit Xanthomonas campestris.

The ISME journal·2026
Same author

The immune cell landscape analysed by imaging mass cytometry in the muscle of patients with inclusion body myositis associated or not with Sjögren's disease.

Rheumatology (Oxford, England)·2026
Same author

Complement activation drives a compartmentalized innate immune response in C3 glomerulopathy contributing to the disease phenotype.

Kidney international·2025

Related Experiment Video

Updated: Jan 25, 2026

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects &#8212; Dual Hind Paw Carrageenan Injection in Mice
06:54

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Published on: November 15, 2024

2.7K

Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters.

Jérémie Babonneau1, Dimitri Bréard2, Marie-Line Reynaert3

  • 1Equipe ATIP AVENIR, CRCINA, INSERM, University of Nantes, University of Angers, Angers, France.

Frontiers in Pharmacology
|April 30, 2019
PubMed
Summary

Mycobacterium ulcerans toxin, mycolactone, rapidly clears from tissue but even small amounts effectively induce long-lasting hypoesthesia, suggesting its potential as a novel analgesic for Buruli ulcer treatment.

Keywords:
Mycobacterium ulceransanalgesiabioavailabilitybiological actionmycolactone

More Related Videos

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability
06:34

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability

Published on: April 28, 2022

5.6K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.1K

Related Experiment Videos

Last Updated: Jan 25, 2026

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects &#8212; Dual Hind Paw Carrageenan Injection in Mice
06:54

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Published on: November 15, 2024

2.7K
The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability
06:34

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability

Published on: April 28, 2022

5.6K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.1K

Area of Science:

  • Infectious Diseases
  • Toxicology
  • Neuroscience

Background:

  • Mycobacterium ulcerans causes Buruli ulcer, the third most common mycobacterial disease globally.
  • The disease's pathology involves panniculitis and ulcerative lesions, driven by the mycolactone toxin.
  • Mycolactone possesses immunomodulatory and analgesic properties, targeting angiotensin II type-2 receptors (AT2R).

Purpose of the Study:

  • To investigate the correlation between mycolactone bioavailability and hypoesthesia at the tissue level.
  • To determine the elimination kinetics of mycolactone following direct tissue injection.
  • To assess the minimum effective mycolactone concentration for inducing hypoesthesia.

Main Methods:

  • Mice received subcutaneous injections of varying mycolactone quantities.
  • Hypoesthesia was measured using nociception assays over 48 hours.
  • Mycolactone levels and diffusion in adjacent tissues and bloodstream were analyzed.

Main Results:

  • Maximal hypoesthesia occurred 6 hours post-injection of 4 μg mycolactone, with nerve function returning to baseline by 48 hours.
  • Mycolactone levels decreased significantly (70% at 4h, 90% at 10h), indicating rapid elimination.
  • Despite rapid clearance, minimal mycolactone amounts were sufficient for sustained hypoesthesia (24h) without significant diffusion.

Conclusions:

  • Intact mycolactone is rapidly eliminated from tissues after injection.
  • Very low concentrations of mycolactone are sufficient to induce prolonged hypoesthesia.
  • Mycolactone demonstrates significant potential as a promising analgesic agent.